Cronos Group Inc vs Boston Beer Company Inc — how do they compare? Cronos Group Inc trades at $3.11 (market cap $1.14B), while Boston Beer Company Inc trades at $183.57 (market cap $1.86B). The key difference: Boston Beer Company Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| CRON | SAM | |
|---|---|---|
Market Cap | $1.14B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $3.27 | $260.05 |
52-Week Low | $2.30 | $161.08 |
Enterprise Value | $341.13M | $1.63B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Boston Beer Company (SAM) trades at $181.95, up 0.53% with bearish technical signals despite recent earnings volatility. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but faces profitability challenges with negative net income margin (-3.64%) and ROE (-8.61%). Recent Q2 2026 earnings missed estimates at $3.65 vs. $4.83 expected, while operating cash flow remains strong at $270M in 2025. Analyst sentiment is cautious with 72% hold ratings amid declining volumes and competitive pressures.
Outlook remains challenging with weak demand impacting core brands, though spirits-based RTD growth and margin improvements offer some support. The consensus price target of $207.33 suggests 14% upside potential, but investors face risks from sustained volume declines, rising marketing costs, and negative earnings growth projections for 2026. The stock's current technical position near pivot point resistance at $182 requires monitoring for breakout confirmation.
Trailing returns across standard periods
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →